© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to July
GPR139 GPCR agonist
oral (40-160 mg QD) Ph. II for schizophrenia
625k-cmpd cell-based screen (21 nM hit) + opt
Journal of Medicinal Chemistry
Takeda, San Diego, US
The Takeda GPR139 agonist, TAK-041, is a CNS-penetrant GPCR agonist being explored for schizophrenia symptoms and is an interesting example of a triazinone-containing clinical candidate. GPR139 is an orphan GPCR…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.